Similar articles

• Immunologic heterogeneity of dihydrofolate reductase from methotrexate sensitive and resistant L1210 leukemia cells.

  Iqbal MP, Rothenberg SP, Larosa C. Iqbal MP, et al. Proc Soc Exp Biol Med. 1985 Oct;180(1):98-102. doi: 10.3181/00379727-180-42149. Proc Soc Exp Biol Med. 1985. PMID: 2412235
• Dihydrofolate reductase activity and loss of resistance in an antifolate-resistant subline of leukemia L1210 after discontinuation of treatment.

  Schrecker AW, Mead JA, Greenberg NH, Goldin A. Schrecker AW, et al. Chem Biol Interact. 1970 Oct;2(3):229-34. doi: 10.1016/0009-2797(70)90025-6. Chem Biol Interact. 1970. PMID: 5289825 No abstract available.
• Limited effectiveness of in vitro high-dose methotrexate and leucovorin to overcome resistance in L1210 leukemia cells with elevations of dihydrofolate reductase.

  Bruckner H, Rubinoff M, Waxman S. Bruckner H, et al. Eur J Cancer (1965). 1980 Aug;16(8):1057-63. doi: 10.1016/0014-2964(80)90253-4. Eur J Cancer (1965). 1980. PMID: 6969180 No abstract available.
• Antifolate resistance and the genetic control of dihydrofolate reductase activity.

  Hutchison DJ. Hutchison DJ. Ann N Y Acad Sci. 1971 Nov 30;186:172-81. doi: 10.1111/j.1749-6632.1971.tb31140.x. Ann N Y Acad Sci. 1971. PMID: 4399850 Review. No abstract available.
• Active-site directed irreversible inhibitors of dihydrofolate reductase.

  Baker BR. Baker BR. Ann N Y Acad Sci. 1971 Nov 30;186:214-26. doi: 10.1111/j.1749-6632.1971.tb31146.x. Ann N Y Acad Sci. 1971. PMID: 4943574 Review. No abstract available.